Sleep biotech is attracting serious investment as pharmaceutical giants recognize the market potential. Eli Lilly paid up to $7.8 billion for Centessa, whose narcolepsy drug enters phase 3 trials, while Ireland's Alkermes acquired Avadel Pharmaceutical for up to $2.4 billion. These deals signal Big Pharma's growing interest in sleep disorder treatments.

The sector's appeal stems from widespread sleep problems affecting about a third of adults in western countries weekly. That exceeds the population eligible for weight-loss drugs, creating a substantial market. Poor sleep carries an estimated national cost of up to $130 billion in lost productivity, according to Rand Europe, as insomniacs would trade 14% of annual income for better rest.

Despite the economic incentives, drug development faces hurdles with a 15-year timeline and $2 billion-plus costs. Much funding flows to sleep tech companies like Oura and Whoop, while biotech startups such as astronauTx aim to treat neurological conditions through improved sleep. New technologies, including AI and wearable devices like Beacon's headband, promise to shrink development timeframes and costs.